Antiseptic-bonded central venous catheters and bacterial colonisation.
This study was undertaken to evaluate the impact of chlorhexidine/silver sulphadiazine-bonded catheters on the incidence of colonisation and catheter-related sepsis in critically ill patients. Threehundred and fifty-one catheters were inserted into 228 patients during the study period, 174chlorhexidine/silver sulphadiazine-bonded catheters and 177 standard catheters. Indications for catheter removal were: death, clinical redundancy and clinical evidence of local or systemic infection. All catheter tips were sent to the microbiology laboratory for semiquantitative analysis of bacterial colony count. Seventy-one (40.2%) of the standard catheters and 47 (27.2%) of the antiseptic-bonded catheters were found to be colonised on removal (p < 0.01). Eight cases (4.7%) of catheter-related sepsis were associated with standard catheters and three cases (1.7%) with antiseptic-bonded catheters, however, this reduction was not statistically significant. Our results indicate that the use of antiseptic-bonded catheters in critically ill patients significantly reduces the incidence of bacterial colonisation.
Hannan
M
M
Department of Medical Microbiology, Imperial College School of Medicine, Westminster Hospital, 369 Fullham Road, London SW10 9NH, UK.
Juste
R N
RN
Umasanker
S
S
Glendenning
A
A
Nightingale
C
C
Azadian
B
B
Soni
N
N
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents; D000891:Anti-Infective Agents, Local / Q000627:therapeutic use*; D016470:Bacteremia / Q000209:etiology / Q000517:prevention & control*; D002405:Catheterization, Central Venous / Q000009:adverse effects / Q000295:instrumentation*; D002710:Chlorhexidine / Q000627:therapeutic use; D003422:Critical Care / Q000379:methods; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D013293:Enterococcus faecalis / Q000302:isolation & purification; D004866:Equipment Contamination / Q000517:prevention & control*; D006801:Humans; D008875:Middle Aged; D012837:Silver Sulfadiazine / Q000627:therapeutic use; D013212:Staphylococcus epidermidis / Q000302:isolation & purification
D000900:Anti-Bacterial Agents; D000891:Anti-Infective Agents, Local; D002710:Chlorhexidine; D012837:Silver Sulfadiazine